A review of second-look laparotomy for ovarian cancer

Cain, Joanna M.; Saigo, Patricia E.; Pierce, Virginia K.; Clark, D.J.; Jones, Walter B.; Smith, Daniel H.; Hakes, Thomas B.; Ochoa, Manuel; Lewis, John L.

doi:10.1016/0090-8258(86)90110-1

Cited by 92 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our experience, this has not been the case. Our results, moreover, cor roborate those reported recently by others [6,7], In contrast are those reported by Bruckner et al [4] and Mangioni et al [5] who found a positive correlation between the use of cisplatin and prognosis, although their results pertain only to patients in advanced stages III and IV of the disease.…”

Section: Discussioncontrasting

confidence: 57%

“…As more reports about large series involving the use of second-look laparotomy appear, the presumed superiority of cisplatin over other agents begins to be controversial. Smirz et al [6] and Cain et al [7] con clude that it offers no advantage over other regimens, whereas Bruckner et al [4] found a positive correla tion between cisplatin and tumor response.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Cisplatin-Containing versus Cisplatin-Free Adjuvant Chemotherapy in Ovarian Carcinoma

Schneider

Martin²,

Erasun³

et al. 1990

Oncology

View full text Add to dashboard Cite

In 1980, second-look laparotomy was introduced simultaneously into the treatment regimen for ovarian carcinoma at the two main referral centers of northern Spain. First-line chemotherapy after initial surgery was, however, different at both hospitals. At one of them (Bilbao), a combination involving the use of cisplatin was employed (cyclophosphamide 600 mg/m², Adriamycin 45 mg/m², and cisplatin 80 mg/m² i.v. on day 1), whereas the patients of the other hospital were treated mainly with single-agent chemotherapy (melphalan 0.2 mg/kg p.o. on days 1–5) and never with a cisplatin combination as first-line therapy in any case. In all, 92 patients (42 stage I, 14 stage II, 33 stage III, and 3 stage IV) could be treated during the study period with optimal surgery (complete tumor excision or largest residual tumor less than 2 cm in diameter). This was followed by adjuvant chemotherapy for 12–18 months in all cases, except for 18 patients with a stage la borderline or G₁tumor. The latter were merely kept under observation until their second-look laparotomy after 1 year of negative follow-up. All of the 74 patients who received adjuvant chemotherapy, of whom 36 with cisplatin and 38 without, were clinically disease free after at least twelve courses of treatment and had a second-look laparotomy performed. This was positive in 33.3% of the cases after cisplatin-containing therapy and in 26.3% of the cases after cisplatin-free therapy. This difference is not statistically significant. The mean follow-up period after negative second-look was 34 months. The long-term results of both patient groups were comparable as far as rate of positive second-look laparotomies and survival rate, overall and stage for stage are concerned. The use of cisplatin did not result in any significant therapeutic improvement. It was uniformly bad tolerated by the patients and carried higher cost, since all patients had to be hospitalized for treatment.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Introductionmentioning

confidence: 98%

Cisplatin-Containing versus Cisplatin-Free Adjuvant Chemotherapy in Ovarian Carcinoma

Schneider

Martin²,

Erasun³

et al. 1990

Oncology

View full text Add to dashboard Cite

show abstract

“…This is emphasised by the subset analyses of the 10 patients in pathological complete remission, and in the poor risk intra-abdominal disease patients (Figure 3) given both treatments. A negative second-look procedure confirms the first requirement has been met for a treatment approach designed to achieve prolonged survival, but almost certainly further consolidation chemotherapy or radiation therapy is required to improve the long term results in this disease (Sutton et al, 1986;Cain et al, 1986). In the 3 patients given abdominopelvic radiotherapy where macroscopic disease was present, the short survival would indicate this treatment was of little benefit in this group.…”

Section: Discussionmentioning

confidence: 96%

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer

Green

Warenius²,

Errington³

et al. 1988

Br J Cancer

View full text Add to dashboard Cite

Summary Forty-six previously untreated patients with advanced ovarian cancer were treated with combination chemotherapy comprising cisplatin 80mgm 2 i.v. and cyclophosphamide 1 gm-2 i.v. every 28 days for 5 cycles. Eighty-five percent of patients received more than 75% of the calculated doses, and of 43 evaluable patients, a complete response was achieved in 31 (72%), a partial response in 4 (9.3%) and 8 patients had static or progressive disease. The actuarial survival of the whole group is 60% at a median follow-up of 2 years. Twenty-four patients in complete clinical or pathological remission were then treated with whole abdominal radiotherapy 2,500cGy followed by a pelvic boost of 2,000cGy. The pelvic boost was omitted in 3 patients, and the overall radiotherapy treatment time extended in a further 4 patients on account of myelosuppression. The actuarial survival of the 24 patients receiving both treatments at a median of 30 months follow-up is 75%. In the 10 patients with negative second-look procedures completing both treatments there have been no tumour related deaths at a median follow-up of 33 months.

show abstract

“…Prognostic values of second-look laparotomy have been stated in several series (26)(27)(28)(29). Complete pathologic response is, however, not equivalent to cure (16).…”

Section: Resultsmentioning

confidence: 99%

Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

Tropé¹,

Andersson²,

Björkholm³

et al. 1996

Acta Oncologica

View full text Add to dashboard Cite

A review of second-look laparotomy for ovarian cancer

Cited by 92 publications

References 16 publications

Cisplatin-Containing versus Cisplatin-Free Adjuvant Chemotherapy in Ovarian Carcinoma

Cisplatin-Containing versus Cisplatin-Free Adjuvant Chemotherapy in Ovarian Carcinoma

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer

Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

Contact Info

Product

Resources

About